Truist cuts Stryker stock price target on revised forecasts
Truist Securities lowered its price target for Stryker Corp. (SYK) to $310 from $340, maintaining a Hold rating. The stock is down 18% year-to-date. The adjustment follows Stryker's CEO transition announcement, with Spencer Stiles set to replace Kevin Lobo in 2027. Truist also revised revenue and earnings forecasts downward, citing management commentary. Multiple analysts have recently adjusted their price targets and estimates for Stryker.
How this was made
The 30-second read
Why it matters
The consensus downgrade lowers near‑term price expectations, but long‑term fundamentals remain intact.
Market read
The target cuts and exec change create short‑term downside risk for SYK.
What to watch
Potential upside from upcoming product launches and international market expansion.
Background
Truist and other sell‑side firms revised SYK forecasts following a planned CEO succession and operational challenges.
Ticker impact
Truist lowered SYK price target to $310 and cut revenue/earnings forecasts after the CEO transition announcement.
likely pressure as the market prices in lower guidance and target.
Multiple analysts cut targets and forecasts on the same day, indicating consensus bearish view.
Market effects
Medical device sector may see broader scrutiny as earnings forecasts tighten.
U.S. healthcare stocks could face modest sell pressure.
Limited to investors with exposure to SYK and peers.
Counterpoint
Some analysts maintain a bullish outlook, citing long‑term growth opportunities in orthopedics.
Key entities
- analystTruist Securities
Provided the price‑target cut and forecast revisions.
- executiveSpencer Stiles
Announced to become CEO on Jan 1, 2027.
